Efficient product cleavage in template-free enzymatic synthesis of polynucleotides

ABSTRACT

The present invention is directed to methods and kits for template-free enzymatic synthesis of polynucleotides that include or enable a step of efficiently cleaving the polynucleotide products from its initiator using endonuclease V activity and initiator with a 3′-penultimate deoxyinosine.

RELATED APPLICATIONS

This application is a U.S. National Stage Entry of InternationalApplication No. PCT/EP2020/053417, entitled “EFFICIENT PRODUCT CLEAVAGEIN TEMPLATE-FREE ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDES,” and filed Feb.11, 2020, which claims the benefit and priority of European ApplicationNo. EP19305174.5 filed Feb. 12, 2019. All above-identified applicationsare hereby incorporated by reference in their entireties.

INCORPORATION OF SEQUENCE LISTING

A computer readable form of the Sequence Listing is filed with thisapplication by electronic submission and is incorporated into thisapplication by reference in its entirety. The Sequence Listing iscontained in the file created on Jan. 13, 2021, having the file nameP50390US00_SEQ_sub.txt, and is 53,248 bytes in size (as measured in theMS-Windows® operating system).

BACKGROUND

Interest in enzymatic approaches to polynucleotide synthesis hasrecently increased both because of increased demand for syntheticpolynucleotides in many areas, such as synthetic biology, CRISPR-Cas9applications, high-throughput sequencing, and the like, and because ofthe limitations of chemical approaches to polynucleotide synthesis,Jensen et al, Biochemistry, 57: 1821-1832 (2018). Currently, mostenzymatic approaches employ a template-free polymerase to repeatedly add3′-O-blocked nucleoside triphosphates to a single stranded initiator oran elongated strand attached to a support followed by deblocking until apolynucleotide of the desired sequence is obtained. Among the challengesof devising a practical implementation of such enzymatic synthesis is tofind a cost-effective and efficient way to cleave a desiredpolynucleotide product from the initiator sequence and the support.

In view of the above, enzymatic synthesis of polynucleotides would beadvanced if methods were available for high efficiency cleavage ofpolynucleotide products from their single stranded initiators.

SUMMARY OF THE INVENTION

The present invention is directed to methods and kits for template-freeenzymatic synthesis of polynucleotides that include or enable a step ofefficiently cleaving the polynucleotide products from its initiatorusing an endonuclease V activity.

In one aspect, methods of the invention include a method of synthesizingpolynucleotides of a predetermined sequence with the following steps: a)providing an initiator having a deoxyinosine penultimate to a3′-terminal nucleotide having a free 3′-hydroxyl; b) repeating cycles of(i) contacting under elongation conditions the initiator or elongatedfragments having free 3′-O-hydroxyls with a 3′-O-blocked nucleosidetriphosphate and a template-independent DNA polymerase so that theinitiator or elongated fragments are elongated by incorporation of a3′-O-blocked nucleoside triphosphate to form 3′-O-blocked elongatedfragments, and (ii) deblocking the elongated fragments to form elongatedfragments having free 3′-hydroxyls, until the polynucleotide is formed;and c) treating the polynucleotide with an endonuclease V activity tocleave the polynucleotide from the initiator.

The present invention advantageously overcomes the above problems in thefield of enzymatic polynucleotide synthesis by providing an initiatorhaving a deoxyinosine at the penultimate position from its 3′ end. Thispermits efficient cleavage of the single stranded initiator at itsterminal nucleotide releasing a polynucleotide product with a5′-monophosphate.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. illustrates an experimental set up for demonstrating thecleavage efficiency of the present invention.

FIG. 2 shows data comparing efficiencies of USER/deoxyuridine cleavageand Endo V/inosine cleavage.

DETAILED DESCRIPTION OF THE INVENTION

The general principles of the invention are disclosed in more detailherein particularly by way of examples, such as those shown in thedrawings and described in detail. It should be understood, however, thatthe intention is not to limit the invention to the particularembodiments described. The invention is amenable to variousmodifications and alternative forms, specifics of which are shown forseveral embodiments. The intention is to cover all modifications,equivalents, and alternatives falling within the principles and scope ofthe invention.

The practice of the present invention may employ, unless otherwiseindicated, conventional techniques and descriptions of organicchemistry, molecular biology (including recombinant techniques), cellbiology, and biochemistry, which are within the skill of the art. Suchconventional techniques may include, but are not limited to, preparationand use of synthetic peptides, synthetic polynucleotides, monoclonalantibodies, nucleic acid cloning, amplification, sequencing andanalysis, and related techniques. Protocols for such conventionaltechniques can be found in product literature from manufacturers and instandard laboratory manuals, such as Genome Analysis: A LaboratoryManual Series (Vols. I-IV); PCR Primer: A Laboratory Manual; andMolecular Cloning: A Laboratory Manual (all from Cold Spring HarborLaboratory Press); Lutz and Bornscheuer, Editors, Protein EngineeringHandbook (Wiley-VCH, 2009); Hermanson, Bioconjugate Techniques, SecondEdition (Academic Press, 2008); and like references.

The present invention is based in part on a recognition and appreciationof the efficiency of using an endonuclesase V activity and adeoxyinosine penultimate to the 3′ terminal nucleotide of an initiatorto cleave a polynucleotide product from an initiator, as compared toother cleavable nucleotides, such as deoxyuridine. In one aspect, it isbelieved that synthesis initiation by a terminal deoxynucleotidyltransferase (TdT) on an initiator with a penultimate deoxyinosine ismuch more efficient than initiation on other cleavable nucleotideconfigurations.

FIG. 1 provides a diagram of a template-free enzymatic synthesis methodemploying initiators with a penultimate deoxyinosine. Shown in thisdepiction are initiators (100) attached by their 5′ ends to solidsupport (105). Each initiator (102) has a 3′-penultimate deoxyinosine(104) next to 3′-terminal nucleotide (106) that has a free 3′ hydroxyl.After a predetermined number of cycles of enzymatic incorporation andde-blocking, a polynucleotide product is formed that is attached tosolid support (105) by initiators (102). The polynucleotide product iscleaved from initiators (102) and support (105) by treating the attachedproduct with an endonuclease V activity which recognizes the presence ofthe deoxyinosine and cleaves the strand on the 3′ side (112) of terminalnucleotide (106) of the initiators. In some embodiments, theendonuclease V activity is provided by using a prokaryotic endonucleaseV. In still other embodiments, the endonuclease V is an E. coliendonuclease V. As used herein, the term “endonuclease V activity” meansan enzyme activity that catalyzes the following cleavage reaction in asingle stranded DNA: 5′ . . . NNINNNN . . . -3′→5′- . . .NNIN+5′-PO₄—NNNN . . . -3′ where N is any nucleotide and I isdeoxyinosine. Cleavage (114) of polynucleotides (116) by an endonucleaseV activity leaves a 5′-monophosphate on the polynucleotides, whichoptionally may be removed by a step of treating them with a5′-phosphatase.

Enzymes with endonuclease V activity are available from commercialenzyme suppliers, for example, New England Biolabs (Beverly, Mass.,USA), NzyTech (Lisbon, Portugal). Such enzymes may be used with thesupplier's recommended cleavage buffers (e.g. 50 mM K—Ac, 20 mM Tris-Ac,10 mM Mg—Ac, 1 mM DTT at pH 7.9). Typical cleavage conditions are asfollows: 70U of Endo V in 50 μl of Nzytech buffer at 37° C. for 500 pmolsynthesis scale on resin. Typical cleavage times are from 5 to 60minutes, or from 10 to 30 minutes. Optionally, endonuclease activity ofthe above enzymes may be heat inactivated by incubation at 65° C. orhigher for 20 minutes. Optionally, the Nzytech endonuclease V comprisesa His tag that allows convenient removal of the enzyme from reactionmixtures in preparation of final products.

Template-Free Enzymatic Synthesis

Template-free enzymatic synthesis of polynucleotides may be carried outby a variety of known protocols using template-free polymerases, such asterminal deoxynucleotidyl transferase (TdT), including variants thereofengineered to accommodate more efficiently 3′-O-blocked deoxynucleosidetriphosphates (3′-O-blocked dNTPs), e.g. Ybert et al, Internationalpatent publication WO/2015/159023; Ybert et al, International patentpublication WO/2017/216472; Hyman, U.S. Pat. No. 5,436,143; Hiatt et al,U.S. Pat. No. 5,763,594; Jensen et al, Biochemistry, 57: 1821-1832(2018); Mathews et al, Organic & Biomolecular Chemistry, DOI:0.1039/c6ob01371f (2016); Schmitz et al, Organic Lett., 1(11): 1729-1731(1999).

In some embodiments, an ordered sequence of nucleotides is coupled to aninitiator nucleic acid using a TdT in the presence of 3′-O-reversiblyblocked dNTPs in each synthesis step. In some embodiments, the method ofsynthesizing an oligonucleotide comprises the steps of (a) providing aninitiator having a free 3′-hydroxyl; (b) reacting under extensionconditions the initiator or an extension intermediate having a free3′-hydroxyl with a TdT in the presence of a 3′-O-blocked nucleosidetriphosphate to produce a 3′-O-blocked extension intermediate; (c)deblocking the extension intermediate to produce an extensionintermediate with a free 3′-hydroxyl; and (d) repeating steps (b) and(c) until the polynucleotide is synthesized. (Sometime “an extensionintermediate” is also referred to as an “elongation fragment.”) In someembodiments, an initiator is provided as an oligonucleotide attached toa solid support, e.g. by its 5′ end. The above method may also includewashing steps after the reaction, or extension, step, as well as afterthe de-blocking step. For example, the step of reacting may include asub-step of removing unincorporated nucleoside triphosphates, e.g. bywashing, after a predetermined incubation period, or reaction time. Suchpredetermined incubation periods or reaction times may be a few seconds,e.g. 30 sec, to several minutes, e.g. 30 min.

The above method may also include capping step(s) as well as washingsteps after the reacting, or extending, step, as well as after thedeblocking step. As mentioned above, in some embodiments, capping stepsmay be included in which non-extended free 3′-hydroxyls are reacted withcompounds that prevents any further extensions of the capped strand. Insome embodiments, such compound may be a dideoxynucleoside triphosphate.In other embodiments, non-extended strands with free 3′-hydroxyls may bedegraded by treating them with a 3′-exonuclease activity, e.g. Exo I.For example, see Hyman, U.S. Pat. No. 5,436,143. Likewise, in someembodiments, strands that fail to be deblocked may be treated to eitherremove the strand or render it inert to further extensions.

In some embodiments that comprise serial synthesis of oligonucleotides,capping steps may be undesirable as capping may prevent the productionof equal molar amounts of a plurality of oligonucleotides. Withoutcapping, sequences will have a uniform distribution of deletion errors,but each of a plurality of oligonucleotides will be present in equalmolar amounts. This would not be the case where non-extended fragmentsare capped.

In some embodiments, reaction conditions for an extension or elongationstep may comprising the following: 2.0 μM purified TdT; 125-600 μM3′-O-blocked dNTP (e.g. 3′-O—NH₂-blocked dNTP); about 10 to about 500 mMpotassium cacodylate buffer (pH between 6.5 and 7.5) and from about 0.01to about 10 mM of a divalent cation (e.g. CoCl₂ or MnCl₂), where theelongation reaction may be carried out in a 50 μL reaction volume, at atemperature within the range RT to 45° C., for 3 minutes. Inembodiments, in which the 3′-O-blocked dNTPs are 3′-O—NH₂-blocked dNTPs,reaction conditions for a deblocking step may comprise the following:700 mM NaNO₂; 1 M sodium acetate (adjusted with acetic acid to pH in therange of 4.8-6.5), where the deblocking reaction may be carried out in a50 μL volume, at a temperature within the range of RT to 45° C. for 30seconds to several minutes.

Depending on particular applications, the steps of deblocking and/orcleaving may include a variety of chemical or physical conditions, e.g.light, heat, pH, presence of specific reagents, such as enzymes, whichare able to cleave a specified chemical bond. Guidance in selecting3′-O-blocking groups and corresponding de-blocking conditions may befound in the following references, which are incorporated by reference:U.S. Pat. Nos. 5,808,045; 8,808,988; International patent publicationWO91/06678; and references cited below. In some embodiments, thecleaving agent (also sometimes referred to as a de-blocking reagent oragent) is a chemical cleaving agent, such as, for example,dithiothreitol (DTT). In alternative embodiments, a cleaving agent maybe an enzymatic cleaving agent, such as, for example, a phosphatase,which may cleave a 3′-phosphate blocking group. It will be understood bythe person skilled in the art that the selection of deblocking agentdepends on the type of 3′-nucleotide blocking group used, whether one ormultiple blocking groups are being used, whether initiators are attachedto living cells or organisms or to solid supports, and the like, thatnecessitate mild treatment. For example, a phosphine, such astris(2-carboxyethyl)phosphine (TCEP) can be used to cleave a3′O-azidomethyl groups, palladium complexes can be used to cleave a3′O-allyl groups, or sodium nitrite can be used to cleave a 3′O-aminogroup. In particular embodiments, the cleaving reaction involves TCEP, apalladium complex or sodium nitrite.

As noted above, in some embodiments it is desirable to employ two ormore blocking groups that may be removed using orthogonal de-blockingconditions. The following exemplary pairs of blocking groups may be usedin parallel synthesis embodiments, such as those described above. It isunderstood that other blocking group pairs, or groups containing morethan two, may be available for use in these embodiments of theinvention.

3′-O—NH2 3′-O-azidomethyl 3′-O—NH2 3′-O-allyl 3′-O—NH2 3′-O-phosphate3′-O-azidomethyl 3′-O-allyl 3′-O-azidomethyl 3′-O-phosphate 3′-O-allyl3′-O-phosphate

Synthesizing oligonucleotides on living cells requires mild deblocking,or deprotection, conditions, that is, conditions that do not disruptcellular membranes, denature proteins, interfere with key cellularfunctions, or the like. In some embodiments, deprotection conditions arewithin a range of physiological conditions compatible with cellsurvival. In such embodiments, enzymatic deprotection is desirablebecause it may be carried out under physiological conditions. In someembodiments specific enzymatically removable blocking groups areassociated with specific enzymes for their removal. For example, ester-or acyl-based blocking groups may be removed with an esterase, such asacetylesterase, or like enzyme, and a phosphate blocking group may beremoved with a 3′ phosphatase, such as T4 polynucleotide kinase. By wayof example, 3′-O-phosphates may be removed by treatment with as solutionof 100 mM Tris-HCl (pH 6.5) 10 mM MgCl₂, 5 mM 2-mercaptoethanol, and oneUnit T4 polynucleotide kinase. The reaction proceeds for one minute at atemperature of 37° C.

A “3′-phosphate-blocked” or “3′-phosphate-protected” nucleotide refersto nucleotides in which the hydroxyl group at the 3′-position is blockedby the presence of a phosphate containing moiety. Examples of3′-phosphate-blocked nucleotides in accordance with the invention arcnucleotidyl-3′-phosphate monoester/nucleotidyl-2′,3′-cyclic phosphate,nucicotidyl-2′-phosphate monoester and nucleotidyl-2′ or3′-alkylphosphate diester, and nucleotidyl-2′ or 3′-pyrophosphate.Thiophosphate or other analogs of such compounds can also be used,provided that the substitution does not prevent dephosphorylationresulting in a free 3′-OH by a phosphatase.

Further examples of synthesis and enzymatic deprotection of3′-O-ester-protected dNTPs or 3′-O-phosphate-protected dNTPs aredescribed in the following references: Canard et al, Proc. Natl. Acad.Sci., 92:10859-10863 (1995); Canard et al, Gene, 148: 1-6 (1994);Cameron et al, Biochemistry, 16(23): 5120-5126 (1977); Rasolonjatovo etal, Nucleosides & Nucleotides, 18(4&5): 1021-1022 (1999); Ferrero et al,Monatshefte fur Chemie, 131: 585-616 (2000); Taunton-Rigby et al, J.Org. Chem., 38(5): 977-985 (1973); Uemura et al, Tetrahedron Lett.,30(29): 3819-3820 (1989); Becker et al, J. Biol. Chem., 242(5): 936-950(1967); Tsien, International patent publication WO1991/006678.

As used herein, an “initiator” (or equivalent terms, such as,“initiating fragment,” “initiator nucleic acid,” “initiatoroligonucleotide,” or the like) refers to a short oligonucleotidesequence with a free 3′-end, which can be further elongated by atemplate-free polymerase, such as TdT. In one embodiment, the initiatingfragment is a DNA initiating fragment. In an alternative embodiment, theinitiating fragment is an RNA initiating fragment. In one embodiment,the initiating fragment possesses between 3 and 100 nucleotides, inparticular between 3 and 20 nucleotides. In one embodiment, theinitiating fragment is single-stranded. In an alternative embodiment,the initiating fragment is double-stranded. In a particular embodiment,an initiator oligonucleotide synthesized with a 5′-primary amine may becovalently linked to magnetic beads using the manufacturer's protocol.Likewise, an initiator oligonucleotide synthesized with a 3′-primaryamine may be covalently linked to magnetic beads using themanufacturer's protocol. A variety of other attachment chemistriesamenable for use with embodiments of the invention are well-known in theart, e.g. Integrated DNA Technologies brochure, “Strategies forAttaching Oligonucleotides to Solid Supports,” v.6 (2014); Hermanson,Bioconjugate Techniques, Second Edition (Academic Press, 2008); and likereferences.

Many of the 3′-O-blocked dNTPs employed in the invention may bepurchased from commercial vendors or synthesized using publishedtechniques, e.g. U.S. Pat. No. 7,057,026; International patentpublications WO2004/005667, WO91/06678; Canard et al, Gene (citedabove); Metzker et al, Nucleic Acids Research, 22: 4259-4267 (1994);Meng et al, J. Org. Chem., 14: 3248-3252 (3006); U.S. patent publication2005/037991. In some embodiments, the modified nucleotides comprise amodified nucleotide or nucleoside molecule comprising a purine orpyrimidine base and a ribose or deoxyribose sugar moiety wherein —Z isany of —C(R′)₂—O—R″, —C(R′)₂—N(R″)₂, —C(R′)₂—N(H)R″, —C(R′)₂—S—R″ and—C(R′)₂—F, wherein each R″ is or is part of a removable protectinggroup; each R′ is independently a hydrogen atom, an alkyl, substitutedalkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic,acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or adetectable label attached through a linking group; with the proviso thatin some embodiments such substituents have up to 10 carbon atoms and/orup to 5 oxygen or nitrogen heteroatoms; or (R′)₂ represents a group offormula=C(R′″)₂ wherein each R′″ may be the same or different and isselected from the group comprising hydrogen and halogen atoms and alkylgroups, with the proviso that in some embodiments the alkyl of each R′″has from 1 to 3 carbon atoms; and wherein the molecule may be reacted toyield an intermediate in which each R″ is exchanged for H or, where Z is—(R′)₂—F, the F is exchanged for OH, SH or NH₂, preferably OH, whichintermediate dissociates under aqueous conditions to afford a moleculewith a free 3′-OH; with the proviso that where Z is —C(R′)₂—S—R″, bothR′ groups are not H. In certain embodiments, R′ of the modifiednucleotide or nucleoside is an alkyl or substituted alkyl, with theproviso that such alkyl or substituted alkyl has from 1 to 10 carbonatoms and from 0 to 4 oxygen or nitrogen heteroatoms. In certainembodiments, —Z of the modified nucleotide or nucleoside is of formula—C(R′)₂—N₃. In certain embodiments, Z is an azidomethyl group.

In some embodiments, Z is a cleavable organic moiety with or withoutheteroatoms having a molecular weight of 200 or less. In otherembodiments, Z is a cleavable organic moiety with or without heteroatomshaving a molecular weight of 100 or less. In other embodiments, Z is acleavable organic moiety with or without heteroatoms having a molecularweight of 50 or less. In some embodiments, Z is an enzymaticallycleavable organic moiety with or without heteroatoms having a molecularweight of 200 or less. In other embodiments, Z is an enzymaticallycleavable organic moiety with or without heteroatoms having a molecularweight of 100 or less. In other embodiments, Z is an enzymaticallycleavable organic moiety with or without heteroatoms having a molecularweight of 50 or less. In other embodiments, Z is an enzymaticallycleavable ester group having a molecular weight of 200 or less. In otherembodiments, Z is a phosphate group removable by a 3′-phosphatase. Insome embodiments, one or more of the following 3′-phosphatases may beused with the manufacturer's recommended protocols: T4 polynucleotidekinase, calf intestinal alkaline phosphatase, recombinant shrimpalkaline phosphatase (e.g. available from New England Biolabs, Beverly,Mass.).

In a further particular embodiment, the 3′-blocked nucleotidetriphosphate is blocked by either a 3′-O-azidomethyl, 3′-O—NH₂ or3′-O-allyl group.

In still other embodiments, 3′-O-blocking groups of the inventioninclude 3′-O-methyl, 3′-O-(2-nitrobenzyl), 3′-O-allyl, 3′-O-amine,3′-O-azidomethyl, 3′-O-tert-butoxy ethoxy, 3′-O-(2-cyanoethyl), and3′-O-propargyl.

In some embodiments, 3′-O— protection groups are electrochemicallylabile groups. That is, deprotection or cleavage of the protection groupis accomplished by changing the electrochemical conditions in thevicinity of the protection group which result in cleavage. Such changesin electrochemical conditions may be brought about by changing orapplying a physical quantity, such as a voltage difference or light toactivate auxiliary species which, in turn, cause changes in theelectrochemical conditions at the site of the protection group, such asan increase or decrease in pH. In some embodiments, electrochemicallylabile groups include, for example, pH-sensitive protection groups thatare cleaved whenever the pH is changed to a predetermined value. Inother embodiments, electrochemically labile groups include protectinggroups which are cleaved directly whenever reducing or oxidizingconditions are changed, for example, by increasing or decreasing avoltage difference at the site of the protection group.

In some embodiments, enzymatic synthesis methods employ TdT variantsthat display increased incorporation activity with respect to3′-O-modified nucleoside triphosphates. For example, such TdT variantsmay be produced using techniques described in Champion et al, U.S.patent Ser. No. 10/435,676, which is incorporated herein by reference.In some embodiments, a TdT variant is employed having an amino acidsequence at least 60 percent identical to SEQ ID NO: 2 and asubstitution at a first arginine at position 207 and a substitution at asecond arginine at position 325, or functionally equivalent residuesthereof. In some embodiments, a terminal deoxynucleotidyl transferase(TdT) variant is employed that has an amino acid sequence at least sixtypercent identical to an amino acid sequence selected from SEQ ID NO: 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 with a substitution ofarginine (“first arginine”) at position 207 with respect to SEQ ID NOs2, 3, 4, 6, 7, 9, 12 and 13, at position 206 with respect to SEQ ID NO5, at position 208 with respect to SEQ ID NOs 8 and 10, at position 205with respect to SEQ ID NO 11, at position 216 with respect to SEQ ID NO14 and at position 210 with respect to SEQ ID NO 15; and a substitutionof arginine (“second arginine”) at position 325 with respect to SEQ IDNOs 2, 9 and 13, at position 324 with respect to SEQ ID NOs 3 and 4, atposition 320 with respect to SEQ ID NO 320, at position 331 with respectto SEQ ID NOs 6 and 8, at position 323 with respect to SEQ ID NO 11, atposition 328 with respect to SEQ ID NOs 12 and 15, and at position 338with respect to SEQ ID NO 14; or functionally equivalent residuesthereof; wherein the TdT variant (i) is capable of synthesizing anucleic acid fragment without a template and (ii) is capable ofincorporating a 3′-O-modified nucleotide onto a free 3′-hydroxyl of anucleic acid fragment. In some embodiments, the above percent identityvalue is at least 80 percent identity with the indicated SEQ ID NOs; insome embodiments, the above percent identity value is at least 90percent identity with the indicated SEQ ID NOs; in some embodiments, theabove percent identity value is at least 95 percent identity with theindicated SEQ ID NOs; in some embodiments, the above percent identityvalue is at least 97 percent identity; in some embodiments, the abovepercent identity value is at least 98 percent identity; in someembodiments, the above percent identity value is at least 99 percentidentity. As used herein, the percent identity values used to compare areference sequence to a variant sequence do not include the expresslyspecified amino acid positions containing substitutions of the variantsequence; that is, the percent identity relationship is betweensequences of a reference protein and sequences of a variant proteinoutside of the expressly specified positions containing substitutions inthe variant. Thus, for example, if the reference sequence and thevariant sequence each comprised 100 amino acids and the variant sequencehad mutations at positions 25 and 81, then the percent homology would bein regard to sequences 1-24, 26-80 and 82-100.

In regard to (ii), such 3′-O-modified nucleotide may comprise a3′-O—NH₂-nucleoside triphosphate, a 3′-O-azidomethyl-nucleosidetriphosphate, a 3′-O-allyl-nucleoside triphosphate, a3′O-(2-nitrobenzyl)-nucleoside triphosphate, or a3′-O-propargyl-nucleoside triphosphate.

In some embodiments, TdT variants used in the invention havesubstitutions as shown in Table 1 or functionally equivalent residuepositions in other TdTs.

TABLE 1 SEQ ID NO Substitutions 1 M192R/Q C302G/R R336L/N R454P/N/A/VE457N/L/T/S/K 2 M63R/Q C173G/R R207L/N R325P/N/A/V E328N/L/T/S/K 3M63R/Q C173G/R R207L/N R324P/N/A/V E327N/L/T/S/K 4 M63R/Q C173G/RR207L/N R324P/N/A/V E327N/L/T/S/K 5 — C172G/R R206L/N R320P/N/A/V — 6M63R/Q C173G/R R207L/N R331P/N/A/V E334N/L/T/S/K 7 M63R/Q C173G/RR207L/N — E328N/L/T/S/K 8 — C174G/R R208L/N R331P/N/A/V E334N/L/T/S/K 9M73R/Q C173G/R R207L/N R325P/N/A/V E328N/L/T/S/K 10 M64R/Q C174G/RR208L/N — E329N/L/T/S/K 11 M61R/Q C171G/R R205L/N R323P/N/A/VE326N/L/T/S/K 12 M63R/Q C173G/R R207L/N R328P/N/A/V E331N/L/T/S/K 13 —C173G/R R207L/N R325P/N/A/V E328N/L/T/S/K 14 M63R/Q C182G/R R216L/NR338P/N/A/V E341N/L/T/S/K 15 M66R/Q C176G/R R210L/N R328P/N/A/VE331N/L/T/S/K

TdT variants of the invention as described above each comprise an aminoacid sequence having a percent sequence identity with a specified SEQ IDNO, subject to the presence of indicated substitutions. In someembodiments, the number and type of sequence differences between a TdTvariant of the invention described in this manner and the specified SEQID NO may be due to substitutions, deletion and/or insertions, and theamino acids substituted, deleted and/or inserted may comprise any aminoacid. In some embodiments, such deletions, substitutions and/orinsertions comprise only naturally occurring amino acids. In someembodiments, substitutions comprise only conservative, or synonymous,amino acid changes, as described in Grantham, Science, 185: 862-864(1974). That is, a substitution of an amino acid can occur only amongmembers of its set of synonymous amino acids. In some embodiments, setsof synonymous amino acids that may be employed are set forth in Table2A.

TABLE 2A Synonymous Sets of Amino Acids I Amino Acid Synonymous Set SerSer, Thr, Gly, Asn Arg Arg, Gln, Lys, Glu, His Leu Ile, Phe, Tyr, Met,Val, Leu Pro Gly, Ala, Thr, Pro Thr Pro, Ser, Ala, Gly, His, Gln, ThrAla Gly, Thr, Pro, Ala Val Met, Tyr, Phe, Ile, Leu, Val Gly Gly, Ala,Thr, Pro, Ser Ile Met, Tyr, Phe, Val, Leu, Ile Phe Trp, Met, Tyr, Ile,Val, Leu, Phe Tyr Trp, Met, Phe, Ile, Val, Leu, Tyr Cys Cys, Ser, ThrHis His, Glu, Lys, Gln, Thr, Arg Gln Gln, Glu, Lys, Asn, His, Thr, ArgAsn Asn, Gln, Asp, Ser Lys Lys, Glu, Gln, His, Arg Asp Asp, Glu, Asn GluGlu, Asp, Lys, Asn, Gln, His, Arg Met Met, Phe, Ile, Val, Leu Trp Trp

In some embodiments, sets of synonymous amino acids that may be employedare set forth in Table 2B.

TABLE 2B Synonymous Sets of Amino Acids II Amino Acid Synonymous Set SerSer Arg Arg, Lys, His Leu Ile, Phe, Met, Leu Pro Ala, Pro Thr Thr AlaPro, Ala Val Met, Ile, Val Gly Gly Ile Met, Phe, Val, Leu, Ile Phe Met,Tyr, Ile, Leu, Phe Tyr Trp, Met Cys Cys, Ser His His, Gln, Arg Gln Gln,Glu, His Asn Asn, Asp Lys Lys, Arg Asp Asp, Asn Glu Glu, Gln Met Met,Phe, Ile, Val, Leu Trp Trp

Kits

The invention includes kits for carrying out methods of the invention.In some embodiments, a kit of the invention comprises an initiatorattached to a support by a 5′ end and having a deoxyinosine penultimateto a 3′ end and free 3′-hydroxyl. In some embodiments, a kit of theinvention further includes an endonuclease V capable of cleaving aninitiator-polynucleotide conjugate 3′ of a terminal nucleotide of theinitiator. In some such kits, the endonuclease V has a capture moiety topermit removal from a reaction mixture. In some kits, such capturemoiety is a His tag. In some embodiments, initiators of a kit have a3′-terminal sequence of 5′-dI-dT-3′. In some embodiments, initiators ofa kit have a 3′-terminal sequence of 5′-dI-dG-3′. In some embodiments,initiators of a kit have a 3′-terminal sequence of 5′-dI-dA-3′. In someembodiments, initiators of a kit have a 3′-terminal sequence of5′-dI-dT-3′, 5′-dI-dG-3′, or 5′-dI-dA-3′. In some embodiments, suchsupport is a solid support. Such solid support may comprise beads, suchas magnetic bead, a planar solid, such as a glass slide, or a membrane,or the like. In some embodiments, a kit of the invention may furtherinclude a template-free polymerase and 3′-O-blocked nucleosidetriphosphates of one or more of deoxyadenosine, deoxyguanosine,thymidine, deoxyuridine and deoxycytidine. In some kits, suchtemplate-free polymerase may be a TdT. In some embodiments, such TdT maybe a TdT variant described herein. In some embodiments, a kit of theinvention may further include a de-blocking agent which is capable ofremoving 3′ blocking groups from incorporated 3′-O-blocked nucleotides.

Example

In this example, the efficiency of using deoxyinosine/endo V cleavage iscompared to deoxyuridine/USER cleavage and the effects on cleavage ofnucleotides adjacent to dI are assessed. 5′-amino-poly(dT)oligonucleotides containing dI were coupled to carboxyl groups ofmagnetic beads using EDC in a conventional reaction. In all experiments,initiators comprised either (1) a 5′-10mer polyT segment followed by adeoxyinosine and 3′ terminal dT, or (2) a 5′-10mer polyT segmentfollowed by a terminal deoxyuridine. In some experiments, initiatorswere extended by a 20mer polyT segment followed by a final dA labeledwith a Cy5 dye, all using a TdT enzyme and 3′-O—NH₂-blocked nucleosidetriphosphates (except for the labeled terminal dA). In otherexperiments, the initiators were extended by the indicated dinucleotidesequences followed by a 18mer poly(dT) and a final dA labeled with a Cy5dye, all using a TdT enzyme and 3′-O—NH₂-blocked nucleosidetriphosphates (except for the labeled terminal dA). After cleavage asindicated (USER or Endo V), the cleaved labeled polynucleotides wereanalyzed by polyacrylamide gel electrophoresis.

FIG. 2 shows electrophoresis data comparing synthesis products ofinitiators having terminal deoxyuridines with synthesis products ofinitiators having penultimate deoxyinosines. The bands in the fourladders on the left of the gel corresponding to deoxyuridine initiatorsshow failure sequences that are significantly more intense than thecorresponding bands from deoxyinosine initiators in the rightmost 10ladders indicating that initiators with penultimate deoxyinosines resultin more efficient synthesis than initiators with terminal deoxyuridines.

Definitions

Unless otherwise specifically defined herein, terms and symbols ofnucleic acid chemistry, biochemistry, genetics, and molecular biologyused herein follow those of standard treatises and texts in the field,e.g. Kornberg and Baker, DNA Replication, Second Edition (W.H. Freeman,New York, 1992); Lehninger, Biochemistry, Second Edition (WorthPublishers, New York, 1975); Strachan and Read, Human MolecularGenetics, Second Edition (Wiley-Liss, New York, 1999).

“Functionally equivalent” in reference to amino acid positions in two ormore different TdTs means (i) the amino acids at the respectivepositions play the same functional role in an activity of the TdTs, and(ii) the amino acids occur at homologous amino acid positions in theamino acid sequences of the respective TdTs. It is possible to identifypositionally equivalent or homologous amino acid residues in the aminoacid sequences of two or more different TdTs on the basis of sequencealignment and/or molecular modelling. In some embodiments, functionallyequivalent amino acid positions belong to sequence motifs that areconserved among the amino acid sequences of TdTs of evolutionarilyrelated species, e.g. genus, families, or the like. Examples of suchconserved sequence motifs are described in Motea et al, Biochim.Biophys. Acta. 1804(5): 1151-1166 (2010); Delarue et al, EMBO J., 21:427-439 (2002); and like references.

“Kit” refers to any delivery system for delivering materials or reagentsfor carrying out a method of the invention. In the context of reactionassays, such delivery systems include systems and/or compounds (such asdilutants, surfactants, carriers, or the like) that allow for thestorage, transport, or delivery of reaction reagents (e.g., fluorescentlabels, such as mutually quenching fluorescent labels, fluorescent labellinking agents, enzymes, quenching agents, etc. in the appropriatecontainers) and/or supporting materials (e.g., buffers, writteninstructions for performing the assay etc.) from one location toanother. For example, kits include one or more enclosures (e.g., boxes)containing the relevant reaction reagents and/or supporting materials.Such contents may be delivered to the intended recipient together orseparately. For example, a first container may contain an enzyme for usein an assay, while a second or more containers contain mutuallyquenching fluorescent labels and/or quenching agents.

“Mutant” or “variant,” which are used interchangeably, refer topolypeptides derived from a natural or reference TdT polypeptidedescribed herein, and comprising a modification or an alteration, i.e.,a substitution, insertion, and/or deletion, at one or more positions.Variants may be obtained by various techniques well known in the art. Inparticular, examples of techniques for altering the DNA sequenceencoding the wild-type protein, include, but are not limited to,site-directed mutagenesis, random mutagenesis, sequence shuffling andsynthetic oligonucleotide construction. Mutagenesis activities consistin deleting, inserting or substituting one or several amino-acids in thesequence of a protein or in the case of the invention of a polymerase.

“Polynucleotide” or “oligonucleotide” are used interchangeably and eachmean a linear polymer of nucleotide monomers or analogs thereof.Monomers making up polynucleotides and oligonucleotides are capable ofspecifically binding to a natural polynucleotide by way of a regularpattern of monomer-to-monomer interactions, such as Watson-Crick type ofbase pairing, base stacking, Hoogsteen or reverse Hoogsteen types ofbase pairing, or the like. Such monomers and their internucleosidiclinkages may be naturally occurring or may be analogs thereof, e.g.naturally occurring or non-naturally occurring analogs. Non-naturallyoccurring analogs may include PNAs, phosphorothioate internucleosidiclinkages, bases containing linking groups permitting the attachment oflabels, such as fluorophores, or haptens, and the like. Whenever the useof an oligonucleotide or polynucleotide requires enzymatic processing,such as extension by a polymerase, ligation by a ligase, or the like,one of ordinary skill would understand that oligonucleotides orpolynucleotides in those instances would not contain certain analogs ofinternucleosidic linkages, sugar moieties, or bases at any or somepositions. Polynucleotides typically range in size from a few monomericunits, e.g. 5-40, when they are usually referred to as“oligonucleotides,” to several thousand monomeric units. Whenever apolynucleotide or oligonucleotide is represented by a sequence ofletters (upper or lower case), such as “ATGCCTG,” it will be understoodthat the nucleotides are in 5′->3′ order from left to right and that “A”denotes deoxyadenosine, “C” denotes deoxycytidine, “G” denotesdeoxyguanosine, and “T” denotes thymidine, “I” denotes deoxyinosine, “U”denotes uridine, unless otherwise indicated or obvious from context.Unless otherwise noted the terminology and atom numbering conventionswill follow those disclosed in Strachan and Read, Human MolecularGenetics 2 (Wiley-Liss, New York, 1999). Usually polynucleotidescomprise the four natural nucleosides (e.g. deoxyadenosine,deoxycytidine, deoxyguanosine, deoxythymidine for DNA or their ribosecounterparts for RNA) linked by phosphodiester linkages; however, theymay also comprise non-natural nucleotide analogs, e.g. includingmodified bases, sugars, or internucleosidic linkages. It is clear tothose skilled in the art that where an enzyme has specificoligonucleotide or polynucleotide substrate requirements for activity,e.g. single stranded DNA, RNA/DNA duplex, or the like, then selection ofappropriate composition for the oligonucleotide or polynucleotidesubstrates is well within the knowledge of one of ordinary skill,especially with guidance from treatises, such as Sambrook et al,Molecular Cloning, Second Edition (Cold Spring Harbor Laboratory, NewYork, 1989), and like references. Likewise, the oligonucleotide andpolynucleotide may refer to either a single stranded form or a doublestranded form (i.e. duplexes of an oligonucleotide or polynucleotide andits respective complement). It will be clear to one of ordinary skillwhich form or whether both forms are intended from the context of theterms usage.

“Primer” means an oligonucleotide, either natural or synthetic that iscapable, upon forming a duplex with a polynucleotide template, of actingas a point of initiation of nucleic acid synthesis and being extendedfrom its 3′ end along the template so that an extended duplex is formed.Extension of a primer is usually carried out with a nucleic acidpolymerase, such as a DNA or RNA polymerase. The sequence of nucleotidesadded in the extension process is determined by the sequence of thetemplate polynucleotide. Usually primers are extended by a DNApolymerase. Primers usually have a length in the range of from 14 to 40nucleotides, or in the range of from 18 to 36 nucleotides. Primers areemployed in a variety of nucleic amplification reactions, for example,linear amplification reactions using a single primer, or polymerasechain reactions, employing two or more primers. Guidance for selectingthe lengths and sequences of primers for particular applications is wellknown to those of ordinary skill in the art, as evidenced by thefollowing references that are incorporated by reference: Dieffenbach,editor, PCR Primer: A Laboratory Manual, 2nd Edition (Cold Spring HarborPress, New York, 2003).

“Sequence identity” refers to the number (or fraction, usually expressedas a percentage) of matches (e.g., identical amino acid residues)between two sequences, such as two polypeptide sequences or twopolynucleotide sequences. The sequence identity is determined bycomparing the sequences when aligned so as to maximize overlap andidentity while minimizing sequence gaps. In particular, sequenceidentity may be determined using any of a number of mathematical globalor local alignment algorithms, depending on the length of the twosequences. Sequences of similar lengths are preferably aligned using aglobal alignment algorithm (e.g. Needleman and Wunsch algorithm;Needleman and Wunsch, 1970) which aligns the sequences optimally overthe entire length, while sequences of substantially different lengthsare preferably aligned using a local alignment algorithm (e.g. Smith andWaterman algorithm (Smith and Waterman, 1981) or Altschul algorithm(Altschul et al., 1997; Altschul et al., 2005)). Alignment for purposesof determining percent amino acid sequence identity can be achieved invarious ways that are within the skill in the art, for instance, usingpublicly available computer software available on internet web sitessuch as http://blast.ncbi.nlm.nih.gov/orttp://www.ebi.ac.uk/Tools/emboss/. Those skilled in the art candetermine appropriate parameters for measuring alignment, including anyalgorithm needed to achieve maximal alignment over the full length ofthe sequences being compared. For purposes herein, % amino acid sequenceidentity values refer to values generated using the pair wise sequencealignment program EMBOSS Needle, that creates an optimal globalalignment of two sequences using the Needleman-Wunsch algorithm, whereinall search parameters are set to default values, i.e. Scoringmatrix=BLOSUM62, Gap open=10, Gap extend=0.5, End gap penalty=false, Endgap open=10 and End gap extend=0.5.

A “substitution” means that an amino acid residue is replaced by anotheramino acid residue. Preferably, the term “substitution” refers to thereplacement of an amino acid residue by another selected from thenaturally-occurring standard 20 amino acid residues, rare naturallyoccurring amino acid residues (e.g. hydroxyproline, hydroxylysine,allohydroxylysine, 6-N-methylysine, N-ethylglycine, N-methylglycine,N-ethylasparagine, allo-isoleucine, N-methylisoleucine, N-methylvaline,pyroglutamine, aminobutyric acid, ornithine, norleucine, norvaline), andnon-naturally occurring amino acid residue, often made synthetically,(e.g. cyclohexyl-alanine). Preferably, the term “substitution” refers tothe replacement of an amino acid residue by another selected from thenaturally-occurring standard 20 amino acid residues. The sign “+”indicates a combination of substitutions. The amino acids are hereinrepresented by their one-letter or three-letters code according to thefollowing nomenclature: A: alanine (Ala); C: cysteine (Cys); D: asparticacid (Asp); E: glutamic acid (Glu); F: phenylalanine (Phe); G: glycine(Gly); H: histidine (His); I: isoleucine (Ile); K: lysine (Lys); L:leucine (Leu); M: methionine (Met); N: asparagine (Asn); P: proline(Pro); Q: glutamine (Gin); R: arginine (Arg); S: serine (Ser); T:threonine (Thr); V: valine (Val); W: tryptophan (Trp) and Y: tyrosine(Tyr). In the present document, the following terminology is used todesignate a substitution: L238A denotes that amino acid residue(Leucine, L) at position 238 of the parent sequence is changed to anAlanine (A). A132V/I/M denotes that amino acid residue (Alanine, A) atposition 132 of the parent sequence is substituted by one of thefollowing amino acids: Valine (V), Isoleucine (I), or Methionine (M).The substitution can be a conservative or non-conservative substitution.Examples of conservative substitutions are within the groups of basicamino acids (arginine, lysine and histidine), acidic amino acids(glutamic acid and aspartic acid), polar amino acids (glutamine,asparagine and threonine), hydrophobic amino acids (methionine, leucine,isoleucine, cysteine and valine), aromatic amino acids (phenylalanine,tryptophan and tyrosine), and small amino acids (glycine, alanine andserine).

This disclosure is not intended to be limited to the scope of theparticular forms set forth, but is intended to cover alternatives,modifications, and equivalents of the variations described herein.Further, the scope of the disclosure fully encompasses other variationsthat may become obvious to those skilled in the art in view of thisdisclosure. The scope of the present invention is limited only by theappended claims.

1. A method of synthesizing a polynucleotide having a predeterminedsequence, the method comprising the steps of: a) providing an initiatorhaving a 3′-penultimate deoxyinosine and a 3′-terminal nucleotide havinga free 3′-hydroxyl; b) repeating cycles of (i) contacting underelongation conditions the initiator or elongated fragments having free3′-O-hydroxyls with a 3′-O-blocked nucleoside triphosphate and atemplate-independent DNA polymerase so that the initiator or elongatedfragments of the initiator are elongated by incorporation of a3′-O-blocked nucleoside triphosphate to form 3′-O-blocked elongatedfragments, and (ii) deblocking the elongated fragments to form elongatedfragments having free 3′-hydroxyls, until the polynucleotide is formed;and c) treating the polynucleotide with an endonuclease V activity tocleave the polynucleotide from the initiator; wherein the 3′-O-blockednucleoside triphosphate has a blocking group attached to a 3′-oxygenwhich prevents successive incorporation of more than one 3′-O-blockednucleoside triphosphate to the same initiator or elongated fragment inthe same cycle.
 2. The method of claim 1, wherein said endonuclease Vactivity is provided by a prokaryotic endonuclease V.
 3. The method ofclaim 2, wherein said prokaryotic endonuclease V is an E. coliendonuclease V.
 4. The method of claim 2, further comprising a step ofremoving said prokaryotic endonuclease V from said cleavedpolynucleotide.
 5. The method of claim 1, to wherein saidtemplate-independent DNA polymerase is a terminal deoxynucleotidyltransferase.
 6. The method of claim 1, wherein said initiator isattached to a support by a 5′ end.
 7. The method of claim 6, whereinsaid support is a solid support.
 8. The method of claim 1, wherein saidinitiator has a 3′-terminal sequence of 5′-dI-dT-3′.
 9. The method ofclaim 1, wherein said polynucleotide cleaved from said initiator has a5′-monophosphate.
 10. A kit for enzymatically synthesizing apolynucleotide comprising an initiator attached to a support by a 5′ endand having a 3′-penultimate deoxyinosine and a 3′-terminal nucleotidehaving a free 3′-hydroxyl.
 11. The kit of claim 10, further comprisingan endonuclease V capable of cleaving an initiator-polynucleotideconjugate 3′ of a terminal nucleotide of the initiator.
 12. The kit ofclaim 10, further comprising said initiator with a 3′-terminal sequenceof 5′-dI-dT-3′.
 13. The kit of claim 10, wherein said support is a solidsupport.
 14. The kit of claim 10, further comprising a template-freepolymerase and 3′-O-blocked nucleoside triphosphate for one or more ofdeoxyadenosine, deoxyguanosine, thymidine, deoxyuridine anddeoxycytidine, wherein the 3′-O-blocked nucleoside triphosphate has ablocking group attached to a 3′-oxygen which prevents successiveincorporation of more than one 3′-O-blocked nucleoside triphosphate tothe same initiator or elongated fragment in the same cycle.
 15. The kitof claim 14, further comprising a de-blocking agent capable of removingsaid blocking group from said 3′-oxygen of an incorporated nucleotide.16. The kit of claim 14, wherein said 3′-O-blocked nucleosidetriphosphates are 3′-O—NH₂-nucleoside triphosphates.
 17. The method ofclaim 1, wherein said blocking group attached to said 3′-oxygen isselected from the group consisting of azidomethyl, amino, and allyl.